Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Up – What’s Next?

Nuvectis Pharma, Inc. (NASDAQ:NVCT)’s stock price gapped up before the market opened on Friday . The stock had previously closed at $19.23, but opened at $20.30. Nuvectis Pharma shares last traded at $19.1150, with a volume of 11,819 shares traded.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on NVCT shares. UBS Group set a $33.00 price objective on Nuvectis Pharma in a research report on Monday, July 6th. Roth Capital raised their target price on Nuvectis Pharma from $20.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday, July 6th. Weiss Ratings lowered shares of Nuvectis Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 5th. HC Wainwright increased their price objective on shares of Nuvectis Pharma from $13.00 to $39.00 and gave the company a “buy” rating in a research note on Monday, June 22nd. Finally, Wall Street Zen raised shares of Nuvectis Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $35.00.

Nuvectis Pharma Stock Performance

The company has a 50-day moving average of $18.16 and a 200 day moving average of $12.23. The firm has a market cap of $622.28 million, a P/E ratio of -14.58 and a beta of -0.26.

Nuvectis Pharma (NASDAQ:NVCT) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). Sell-side analysts anticipate that Nuvectis Pharma, Inc. will post -0.98 EPS for the current fiscal year.

Insider Buying and Selling at Nuvectis Pharma

In other news, CEO Ron Bentsur purchased 12,500 shares of Nuvectis Pharma stock in a transaction on Tuesday, June 30th. The shares were purchased at an average cost of $20.00 per share, for a total transaction of $250,000.00. Following the completion of the transaction, the chief executive officer directly owned 3,688,424 shares in the company, valued at approximately $73,768,480. This represents a 0.34% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Marlio Charles Mosseri purchased 50,000 shares of Nuvectis Pharma stock in a transaction on Tuesday, June 30th. The stock was purchased at an average price of $18.32 per share, for a total transaction of $916,000.00. Following the completion of the transaction, the insider owned 3,186,576 shares of the company’s stock, valued at approximately $58,378,072.32. This represents a 1.59% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 28.55% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of NVCT. JPMorgan Chase & Co. raised its position in Nuvectis Pharma by 3,398.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,263 shares of the company’s stock valued at $47,000 after purchasing an additional 6,084 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Nuvectis Pharma in the second quarter valued at $53,000. Bank of America Corp DE raised its holdings in shares of Nuvectis Pharma by 417.2% in the second quarter. Bank of America Corp DE now owns 8,565 shares of the company’s stock valued at $64,000 after buying an additional 6,909 shares during the last quarter. Deutsche Bank AG raised its holdings in shares of Nuvectis Pharma by 3,671.4% in the fourth quarter. Deutsche Bank AG now owns 12,672 shares of the company’s stock valued at $96,000 after buying an additional 12,336 shares during the last quarter. Finally, New York State Common Retirement Fund acquired a new position in Nuvectis Pharma during the 2nd quarter worth about $97,000. 96.77% of the stock is owned by institutional investors and hedge funds.

About Nuvectis Pharma

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.